Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (4491)	6/15/1998 12:38:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

Bill, I don't know for sure but I just bought more (even tho' I don't need it). There is a newspaper article today regarding the "fat redistribution syndrome" (ie., "Crix belly") attributed to protease inhibitors (I don't have complete details). There is no mention of the "buffalo hump" or "protease paunch" ("disfuguring fat deposits") being attributed to Viracept, which, I guess, is always possible (I personally have not seen it). However, the FDA medical officer also commented that "we think the benefits of protease inhibitors still outweigh the risks." Maybe someone can post the article. Also, IMO, there should be no backlash from the deal cut with IMNR, which, financially, should be rather good for AGPH. Somebody else will need to comment.